Stock analysts at StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Stock Down 1.4 %
Shares of RDHL stock opened at $6.44 on Friday. RedHill Biopharma has a one year low of $5.41 and a one year high of $20.27. The stock has a fifty day moving average price of $6.79 and a 200 day moving average price of $57.26.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC acquired a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma at the end of the most recent quarter. 7.20% of the stock is owned by institutional investors.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Further Reading
- Five stocks we like better than RedHill Biopharma
- How to Invest in the FAANG Stocks
- Bloom Energy: Powering the Future With Decentralized Energy
- Stock Analyst Ratings and Canadian Analyst Ratings
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- 5 Top Rated Dividend Stocks to Consider
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.